Good question. I guess it can't be patented, frustrating monopolies and also doesn't fit into big pharma's general business model. Cannabis, particularly taken raw such as in fresh juice or a freeze dried derivative is a remarkable preventative, and profits for the symptom chasing antagonists relying on an unhealthy population suffering the side effects of expensive, often worse than useless drugs for which to prescribe more "relief" would no doubt suffer. The eventuality of cancer is one of the the big money spinners but profit mostly hinges around control of pain relief. Regarding cannabis oil and products in general I'm all in favour of quality control but as you suggest, that's an open arena in which big pharma can compete like anyone else. It's not as if they're exactly disadvantaged, unlike your average Transkei farmer. Cannabis is first and foremost a food like lucerne, corn, wheat etc. and should share that status when it comes to growing it.